>>847
>>848
mRNAããDNAãæ¹å€ããäºãªããŠé«æ ¡ã®çç©ã®ææ¥ããŸãšãã«åãã人éãªãäžå¯èœã ãšèª°ã§ããããwww
>>849
ä»æ®ºãããwww
殺ããããšããŠãçºè¡šããè«æã¯ãããäžã«æ®ãã¯ããªãã§ããæ®ã£ãŠãªãã®ã¯ãªãããªãã
>>850
ã¯ã¯ãã³ãã®ãã®ãæªæ¥çš®ã§ããã
ãã ãåãã®èåç¡çšœãªé ã®æªãçºèšã®ããã§æªæ¥çš®è ãå šå¡ç°åžžè ã®ããã«èŠãããã®ãè¿·æã
>>851
ãã¡ã€ã¶ãŒã®å ¬åŒã«ãã¯ã¯ãã³æ¥çš®è ã®åŒæ°ãæ±ããã¹ãã€ã¯èçœãæ害ç©è³ªãæŸåºããããšæžããŠããããå±éºïŒããšãã人ãž
ãæ²»éšã®è³æã«ãå ¬åŒã®ææžã«ããã¿ã€ãã«ã®ãããªæèšã¯èšèŒãããŠããŸããããæ¥çš®ãé²ãåœããããã®ãããªè©±ã¯å ±åãããŠããŸããã
ãæ ¹æ ã ãšäž»åŒµãããŠããæ²»éšã®è³æã®è©²åœéšåã«ã¯ãã¯ã¯ãã³ã«å¯ŸããŠåžã蟌ãã»ç®èã«è§Šãããšãã£ãæŽé²ãåãã女æ§ãåŠåš ããå Žåã¯ãå ±åããŠãã ããããšããèšèŒ1)ããããŸããããããèªã¿ééãããããããã¯æå³çã«éæ¹é ãããã®ãšæãããŸãã
1) Pfizer PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 â»è©²åœã®èšèŒã¯67ïœ68ããŒãž
ããªãããŠã€ã«ã¹ã«ææããéã¯ãã¯ã¯ãã³ãæ¥çš®ããéã®200ïœ300åã®ã¹ãã€ã¯èçœãäœãããŸããããã«ãã¹ãã€ã¯èçœã ãã§ãªããŠã€ã«ã¹æ¬äœãã®ãã®ã倩æåŠçãªéã«å¢ããŠãå£ã錻ããæŸåºãããããšã«ãªããŸãã
>>848
mRNAããDNAãæ¹å€ããäºãªããŠé«æ ¡ã®çç©ã®ææ¥ããŸãšãã«åãã人éãªãäžå¯èœã ãšèª°ã§ããããwww
>>849
ä»æ®ºãããwww
殺ããããšããŠãçºè¡šããè«æã¯ãããäžã«æ®ãã¯ããªãã§ããæ®ã£ãŠãªãã®ã¯ãªãããªãã
>>850
ã¯ã¯ãã³ãã®ãã®ãæªæ¥çš®ã§ããã
ãã ãåãã®èåç¡çšœãªé ã®æªãçºèšã®ããã§æªæ¥çš®è ãå šå¡ç°åžžè ã®ããã«èŠãããã®ãè¿·æã
>>851
ãã¡ã€ã¶ãŒã®å ¬åŒã«ãã¯ã¯ãã³æ¥çš®è ã®åŒæ°ãæ±ããã¹ãã€ã¯èçœãæ害ç©è³ªãæŸåºããããšæžããŠããããå±éºïŒããšãã人ãž
ãæ²»éšã®è³æã«ãå ¬åŒã®ææžã«ããã¿ã€ãã«ã®ãããªæèšã¯èšèŒãããŠããŸããããæ¥çš®ãé²ãåœããããã®ãããªè©±ã¯å ±åãããŠããŸããã
ãæ ¹æ ã ãšäž»åŒµãããŠããæ²»éšã®è³æã®è©²åœéšåã«ã¯ãã¯ã¯ãã³ã«å¯ŸããŠåžã蟌ãã»ç®èã«è§Šãããšãã£ãæŽé²ãåãã女æ§ãåŠåš ããå Žåã¯ãå ±åããŠãã ããããšããèšèŒ1)ããããŸããããããèªã¿ééãããããããã¯æå³çã«éæ¹é ãããã®ãšæãããŸãã
1) Pfizer PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines) Protocol C4591001 â»è©²åœã®èšèŒã¯67ïœ68ããŒãž
ããªãããŠã€ã«ã¹ã«ææããéã¯ãã¯ã¯ãã³ãæ¥çš®ããéã®200ïœ300åã®ã¹ãã€ã¯èçœãäœãããŸããããã«ãã¹ãã€ã¯èçœã ãã§ãªããŠã€ã«ã¹æ¬äœãã®ãã®ã倩æåŠçãªéã«å¢ããŠãå£ã錻ããæŸåºãããããšã«ãªããŸãã